

KRasG12C inhibitors in clinical trials: a historical perspective

Lisa Goebel,^{*a,b} Matthias P. Müller,^{a,b} Roger S. Goody^c and Daniel Rauh^{a,b}










^aFaculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Strasse 4a, 44227 Dortmund (Germany)

^bDrug Discovery Hub Dortmund (DDHD) am Zentrum für integrierte Wirkstoffforschung (ZIW), 44227 Dortmund (Germany)

^cDepartment of Structural Biochemistry, Max Planck Institute of Molecular Physiology, Otto-Hahn-Strasse 11, 44227 Dortmund (Germany)

Supplementary information

PyMOL Session

PyMOL Scene	PDB ID	Compound	Chemical Structure	Reference
F1	4luc	Compound 6		Ostrem <i>et al.</i> (2013)
F2	4lyh	Compound 9		Ostrem <i>et al.</i> (2013)
F3	6b0v	ARS-107		Patricelli <i>et al.</i> (2016)
F4	5f2e	ARS-853		Patricelli <i>et al.</i> (2016)
F5	5v9u	ARS-1620		Janes <i>et al.</i> (2018)
F6	6p8z	Indole lead 1		Shin <i>et al.</i> (2019)
F7 (overview) F8 (key interactions)	6oim	AMG 510		Canon <i>et al.</i> (2019)
F9	6n2j	Compound 4		Fell <i>et al.</i> (2018)
F10 (overview) F11 (key interactions)	6ut0	MRTX849		Christensen <i>et al.</i> (2019) Fell <i>et al.</i> (2020)
F12	6p8z	Compound 6 Compound 9 ARS-107 ARS-853 ARS-1620 Indole lead 1 AMG 510 Compound 4	Structural comparison of all KRasG12C switch-II pocket inhibitors	-

		MRTX849		
--	--	---------	--	--